

# Ontario Public Drug Programs

## Drug Submission Status

**Generic Name:** ranibizumab

**Brand Name:** Lucentis

**Strength:** 10mg/mL solution for injection

**Manufacturer:** Novartis Pharmaceuticals Canada Inc.

**Indication:** Treatment of visual impairment due to diabetic macular edema (DME)

**Rapid Review:** Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	26/01/2012	24/02/2012	EO decision rendered	Listed on the Ontario Drug Benefit Formulary as a Limited Use Benefit

### Rapid Review:

Details of the Rapid Review process can be found at:  
[www.health.gov.on.ca/english/providers/program/drugs/drug\\_submissions/rapid\\_review\\_process.html](http://www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html)

### Review Status:

- Screening – Ministry is screening the manufacturer’s submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

**Funding Status:**

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at: [www.health.gov.on.ca/english/providers/program/drugs/ced\\_rec\\_table.html](http://www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html)

Updated: December 11, 2012